Det har under en längre tid funnits en stor vilja att under den perioperativa fasen ge patienter höga koncentrationer av syrgas med motiveringen att förbättra vävnadsperfusion och därmed den postoperativa återhämtningen. Nyare studier har påvisat de komplikationer vilka hyperoxygenering skulle kunna medföra i form av ökad mortalitet och morbiditet. Syftet med föreliggande studie var att undersöka huruvida patienter utsätts för hyperoxygenering peroperativt. Studien inkluderade 100 patienter och har genomförts genom en deskriptiv retrospektiv journalgranskning med tillägg av jämförande analyser mellan de undersökta operationsavdelningarna. Huvudresultat för studien var att samtliga undersökta operationsavdelningar hyperoxygenerade patienter under anestesi. För hela det undersökta underlaget uppmättes medelvärdet av parametern maximalt PaO2 till 30,7 ±11,7 kPa och medelvärdet av det genomsnittligt inspiratoriska FiO2 uppmättes till 45,5 ±7,6 %. Det högst uppmätta PaO2-värdet var vid en av de undersökta operationsavdelningarna 66,5 kPa. Slutsatsen vilken kan dras av denna studie är att patienter som undergår anestesi hyperoxygeneras till en nivå som visats innebära ökade risker och hyperoxygenering skulle potentiellt kunna vara ett större peroperativt problem än vad som idag är känt. / For a long period of time, there has been a great desire to provide high concentrations of oxygen in patients during the perioperative phase with the motivation to improve tissue perfusion and postoperative recovery. Recent studies have shown that hyperoxygenation may result in complications such as increased mortality and morbidity. The purpose of the present study was to investigate if patients are exposed to hyperoxygenation perioperatively. The study included 100 patients and was conducted through a descriptive retrospective journal review, with the addition of comparative analyzes between the investigated surgical departments. The main result of the study was that all investigated surgical departments hyperoxygenated patients under anesthesia. For the entire sample material examined, the average parameter of the substrate PaO2 was measured to 30.7 ±11.7 kPa, and the mean of the average inspirational FiO2 was measured to 45,5 ±7,6 %. The highest measured PaO2 value at one of the surgical departments being investigated was 66,5 kPa. In conclusion, the results from this study shows that patients undergoing anesthesia are presently being hyperoxygenated up to a level associated with increased risks, and that hyperoxygenation potentially is a greater peroperative problem than currently known.

Orientador: Fernando Broetto / Banca: Marli Teixeira de Almeida Minhoni / Banca: Adriane Maria Ferreira Milagres / Banca: José Soares do Nascimento / Banca: Renato Mamede de C. Montini / Resumo: O cultivo de cogumelos comestíveis, em subprodutos energéticos, representa o principal exemplo da conversão direta de resíduos lignocelulósicos em um artigo com alto valor agregado, com benefício para o gênero humano e uma fonte de energia biosintética comercialmente importante. O objetivo do trabalho foi verificar a atividade de enzimas lignocelulolíticas do Lentinula edodes crescendo em resíduos agrícolas, utilizando-se três tipos de incubação: meio líquido, sistema estacionário e bioreator. As linhagens LE 95/17, LE 96/22 e Leax foram incubadas em substratos compostos de casca de arroz (CA), serragem de eucalipto (SE), bagaço de mandioca (BM) e bagaço de cana-de-açúcar (BC), suplementado com 20% de farelo de arroz e 1% de CaCO3. Foram avaliados a velocidade de crescimento miceliano e a atividade de enzimas oxidativas e hidrolíticas. As linhagens em meio de cultura líquido não apresentam atividades expressivas de manganês peroxidase e lacase. SE e BC, utilizados no sistema estacionário, mostraram ser os mais eficientes para as atividades de MnP, enquanto que para a atividade da lacase apenas SE. O sistema estacionário, em SE, foi melhor que o bioreator para atividade de enzimas hidrolíticas. O bagaço de mandioca pode ser uma alternativa viável como substrato, ou na forma de complemento à outros substratos, por propiciar um rápido crescimento miceliano. A lignina peroxidase não foi detectada em nenhum dos experimentos. / Abstract: The cultivation of mushrooms in by-products represents the main example of the direct conversion of lignocellulosic residues in an article with high attached value with benefit for the mankind and source of commercially important biosynthetic energy. The aim of this work was verify the activity of the Lentinula edodes lignocellulolitic enzymes growing in agricultural residues utilizing three kinds of incubation: liquid culture medium, solid static state and bioreactor. The LE 17/95, LE 22/96 and Leax strains were incubated in substrates composed of peel of rice (PR), eucalyptus sawdust (ES), cassava bagasse (CB) and sugar cane bagasse (SB), supplemented with 20% of rice brans and 1% of CaCO3. The mycelium growth velocity, the oxidative and hydrolytic enzymes activity were evaluated. The strains in liquid culture medium don't presented expressive activities of manganese peroxidase (MnP) and laccase. SE and BC utilized in solid static state system showed to be more efficient to MnP activity while laccase only SE. The solid static state system was better than bioreactor to hydrolytic enzymes activity in SE. The cassava bagasse can be a substrate alternative for having a fast mycelium growth. The lignin peroxidase was not detected in the experiments. / Doutor

Lipoxygenases (LOXs), cytochromes P450 (CYPs) and cyclooxygenases (COXs) catalyze peroxidation of unsaturated fatty acids. In humans they convert arachidonic acid into a variety of eicosanoids, which play a role in all inflammatory responses, cardiovascular and kidney diseases, Alzheimer's, cancer and other ailments. Blocking one pathway can prompt the body to switch to the available alternatives. In contrast to CYP and COX, LOX has a non-heme iron co-factor. Several LOXs are produced or stress-induced in the human body. They share the same mechanism, but differ in sequence causing catalysis on the same substrate to be regio- and stereospecific. The action of 15-LOXs could be pro- or anti-inflammatory, and pro- or anti-carcinogenic. Depending on the dose, LOXs inhibitors can induce or inhibit other oxygenases. Inhibition of these enzymes presents a great challenge in solving the problem of how to control their action and treat diseases, without causing severe side effects and maintaining/restoring a delicate equilibrium between them. Research on CYPs and COXs is more advanced, while studies of LOXs are lagging behind. This article presents a brief review about LOX structures and inhibition, their involvement in human diseases, and their interplay with other oxidoreductases.

Yes / Studies on the substrate selectivity of recombinant ferrous-iron- and 2-oxoglutarate-dependent proline hydroxylases (PHs) reveal that they can catalyse the production of dihydroxylated 5-, 6-, and 7-membered ring products, and can accept bicyclic substrates. Ring-substituted substrate analogues (such hydroxylated and fluorinated prolines) are accepted in some cases. The results highlight the considerable, as yet largely untapped, potential for amino acid hydroxylases and other 2OG oxygenases in biocatalysis.

In the last decade, dynamic combinatorial mass spectrometry (DCMS) with protein targets has emerged as a promising method for the identification of enzyme-inhibitors. 2-Oxoglutarate (2OG) oxygenases are involved in important biological processes related to many diseases; several human 2OG oxygenases are targeted for pharmaceutical intervention. This thesis describes inhibition studies on three 2OG oxygenases using DCMS and structure activity relation (SAR) studies. Disulphide based DCMS was used for the identification of N-oxalyl based lead inhibitors for the 2OG oxygenase AlkB from Escherichia coli. Crystallographic analyses of AlkB with a lead inhibitor assisted in the design of a second generation of inhibitors using N-oxalyl, pyridyl and quinolinyl scaffolds. Crystallographic and kinetic data of three potent and selective AlkB inhibitors validates the DCMS approach for the development of 2OG oxygenase inhibitors. The hypoxia inducible factor hydroxylase, prolyl hydroxylase domain 2 (PHD2), was then used as the model enzyme for the development of a novel DCMS approach employing the reversible reaction of boronic acids with diols to form boronate esters. The ‘boronate’ DCMS method was used to identify pyridyl- substituted lead compounds. Further modification of the pyridine scaffold, based on structural analyses, led to the development of highly potent and selective PHD2 inhibitors. To identify inhibitors for the fat mass and obesity associated protein (FTO), another 2OG oxygenase, an inhibition assay was developed. The inhibition assay was used in conjunction with a differential scanning fluorimetry (DSF) binding assay to identify isoquinolinyl and pyridyl inhibitor scaffolds, related to those used in the DCMS studies. FTO complexed structures of these compounds, and with a natural product anthraquinone, enabled the design and synthesis of new inhibitors that are both co-substrate and substrate competitors of FTO. One such compound proved to be a potent FTO inhibitor with improved selectivity over other 2OG oxygenases. Overall, the work validates the use of DCMS methods for the development of potent and selective inhibitors for 2OG oxygenases, and by implication of other enzyme families.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2007. / Title from PDF title page (viewed on Feb. 19, 2010). Includes bibliographical references.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 5 uppsatser.

En raison de la complexité de sa pathogenèse, le traumatisme crânien (TC) entraîne de nombreuses lésions cérébrales pour lesquelles il n’existe aucun traitement neuroprotecteur. Il est aujourd’hui clairement établi que la neuro-inflammation est fortement impliquée dans les conséquences post-traumatiques. Cette neuro-inflammation se manifeste entre autres par l’induction de la cyclo-oxygénase de type 2 (COX-2). Bien que plusieurs données soient en faveur d’un rôle délétère de cette enzyme au cours de ce processus dévastateur, l’implication de la COX-2 dans les lésions induites par le TC reste encore controversée. Dans un modèle du TC par percussion mécanique chez la souris, nous avons mis en évidence une augmentation précoce et transitoire du contenu cérébral en COX-2 à 6 et 12 heures après le trauma. Cette induction protéique était à l’origine d’une production accrue de la prostacycline. Cependant, l’inhibition préférentielle de COX-2 était sans effet sur l’œdème cérébral et le déficit neurologique, deux indicateurs de pertinence clinique. Ces données montrent que la COX-2 ne peut pas constituer à elle seule une cible intéressante pour le traitement des conséquences post-traumatiques malgré son induction et son activité après le trauma. Par ailleurs, nous avons montré un effet bénéfique induit par l’indométacine au niveau fonctionnel, ce qui est en faveur d’un rôle délétère des COXs dans le déficit neurologique post-traumatique. Cet effet bénéfique peut impliquer uniquement la COX-1 ou en association avec la COX-2. Ces données constituent un argument supplémentaire qui s’ajoute à plusieurs preuves récentes fournies par la littérature en faveur d’un rôle délétère de COX-1 dans la neuro-inflammation. Malheureusement, ce rôle ne pourra pas être confirmé dans notre modèle car les inhibiteurs sélectifs de COX-1 disponibles à ce jour sont inexploitables dans nos conditions expérimentales. Ce travail constitue une nouvelle piste pour évaluer l’intérêt de l’inhibition des COXs au cours de la phase précoce de la prise en charge du patient traumatisé crânien. La bonne tolérance de l’usage à court terme des inhibiteurs de COX, leur disponibilité sur le marché, leur prix abordable, leur simplicité d’administration, leurs caractéristiques pharmacocinétiques et pharmacodynamiques bien connus sont des facteurs suscitant un intérêt croissant d’élargir le spectre de leurs utilisations en clinique et de la mise en place de nouveaux essais thérapeutiques dans les années à venir. / Because of its complex pathology, Traumatic Brain Injury (TBI) leads to numerous cerebral lesions for which there is no neuroprotective treatment. It is clearly known nowadays that neuro-inflammation is highly involved in post-traumatic consequences. This devastating process is manifested among others by the induction of cyclo-oxygenase type 2 (COX-2). Although many data are in agreement with a deleterious role of COX-2 in neuro-inflammation, the implication of this isoform in the TBI-induced lesions is still controversial. In a mouse model of TBI induced by mechanical percussion, we have shown an early and a transitory increase in the cerebral content of COX-2 at 6 and 12 hours after trauma. This protein induction was the source of an increased production of prostacyclin. However, the preferential inhibition of COX-2 had no effect against cerebral œdema and neurological deficit, two indicators of high clinical relevance. These data show that COX-2 cannot be considered by itself as an interesting target for the treatment of post-traumatic consequences despite its induction and activity after trauma. Besides, we have shown a beneficial effect that was induced by indomethacin at the functional level. This effect highly suggests a deleterious role of COXs in the post-traumatic neurological deficit. This neuroprotection could solely involve COX-1 or both COX isoforms. In accordance with several proofs that were recently supplied by literature, our data constitute an additional argument suggesting a deleterious role of COX-1 in neuro-inflammation. Unfortunately, this hypothesis cannot be confirmed in our model of TBI because the selective inhibitors of COX-1 available this day cannot be exploited in our experimental conditions. This experimental work is a new indication to evaluate the potential interest of COXs inhibition during the early phase of clinical management of patients with TBI. The good tolerance of the short-term intake of COX inhibitors, their availability on the market, their affordable price, their simple way of administration, their well-known pharmacokinetic and pharmacodynamic characteristics increase the need to widen the spectrum of their therapeutic indications and to design new clinical trials during the upcoming years.

The 2OG oxygenases comprise a superfamily of ferrous iron dependent dioxygenases with multiple biological roles, including in hypoxia sensing, transcriptional control, and splicing control. It was recently proposed that 2OG oxygenases catalyse the hydroxylation of ribosomal proteins in prokaryotes (ycfD) and in humans (NO66 and MINA53), raising the possibility that 2OG oxygenases also control translation. The work described in this thesis concerned investigations on the biochemical and functional aspects of prokaryotic and mammalian ribosomal protein hydroxylases (ROX) in vitro and in cells. An efficient chromatographic system linked to mass spectrometric analysis (LC-MS) was developed for studying the masses of individual ribosomal proteins (>90% coverage of ribosomal proteome) to ±1 Da accuracy. It was demonstrated that ycfD catalyses the hydroxylation of R81 on L16 in E. coli, in a manner dependent on atmospheric oxygen levels. YcfD deletion results in growth phenotype at low temperatures and in minimal medium, and in decreased global translation rates in minimal medium; ycfD deletion does not affect translational accuracy and ribosome assembly. Furthermore, ycfD-deletion results in increased sensitivity to the antibiotics chloramphenicol and lincomycin. Consistent with a 2OG-oxygenase mediated mechanism of antibiotic resistance, chloramphenicol sensitivity of the E. coli wild-type strain could be increased by inhibiting the activity of ycfD by removing co-factors required for catalytic activity (Fe(II) and O2), and, at least in part, by using a ycfD inhibitor, IOX1, which inhibits ycfD with IC₅₀ of 38 μM in vitro. The therapeutic potential of a post-translational modification mediating antibiotic resistance provides an opportunity for medicinal targeting of ribosome-modifying enzymes, for example ycfD, which may be more ‘druggable’ than the ribosome itself. In co-treatment with an existing antibiotic, such as chloramphenicol, a small molecule inhibitor would achieve a potentiated antibiotic effect. Structural aspects of ROX hydroxylation were pursued by characterising a thermophilic ROX-substrate complex; a ycfD homologue was identified in the thermophilic bacterium Rhodothermus marinus and shown to be a thermophilic 2OG oxygenase ycfD_RM, acting on R82 of ribosomal protein L16_RM. The activity of ycfD_RM in cells was limited at high growth temperature and oxygen solubility was demonstrated as a likely limiting factor of ycfD_RM activity, thus identifiying a potential 2OG oxygenase oxygen sensor in prokaryotes. A crystal structure of ycfD_RM in complex with L16RM substrate fragment was determined to 3.0 Å resolution. Structural analyses suggested that ycfD_RM contains 30% more hydrophobic interactions and 100% more salt-bridge interactions than ycfD_EC, suggesting that these interactions are important for thermal stabilisation of ycfD_RM. The structures reveal key interactions required for binding of ribosomal proteins. Substantial structural changes were observed in the presence of the substrate fragment, which implies induced-fit binding of the L16_RM substrate. The work has informed further structural studies on the evolutionarily related human ROX, NO66 and MINA53, for which substrate structures have been obtained since the completion of the work. The LC-MS analysis of ribosomal proteins was extended to mouse and human cells to demonstrate that the human ROX homologue of ycfD, MINA53, hydroxylates the 60S ribosomal protein rpL27a in cells. It was demonstrated that rpL27a hydroxylation is widespread and found in all mouse organs analysed, as well as in cancer cell lines and in clinical cancer tissues. A partial or complete reduction of rpL27a hydroxylation was observed in a number of clinically identified MINA53 mutations from the COSMIC database of cancer mutations. Structural analysis suggested that mutations occur more frequently at structurally important regions of MINA53, including the βIV-βV insert in the core fold of MINA53. The identification of inhibiting clinical mutations suggests that rpL27a hydroxylation level could be used as a cancer mark, and in the future for selective inhibition by ribosomal antibiotics. The work presented in this thesis demonstrates that it is possible to selectively inhibit modified ribosomes; an inhibitor of unhydroxylated rpL27a could therefore, at least in principle, be active against the sub-set of tumours with inactivating mutation(s) of MINA53, but not normal tissue. Future work should therefore focus on identifying a selective inhibitor of unhydroxylated eukaryotic ribosomes which could be applied for treatment of cancers harbouring deactivating MINA53 mutations. The same approach could be applied to other ribosome modifications (to rRNA, ribosomal proteins, and ribosome-associate factors) that are different in cancer compared to normal cells.

JMJD6 or PSR (phosphatidyl serine receptor) was initially proposed to be a membrane receptor involved in apoptotic cell clearance by recognition of apoptotic cells. However, sequence analyses implied the presence of a jelly roll or double stranded beta helix (DSBH) structural domain in PSR/JMJD6 and similarity with JmjC family of enzymes which are involved in chromatin regulation. Subsequently, PSR was renamed as JMJD6 and was reported to be a histone arginine demethylase. Previous work from our group has shown that JMJD6 is a lysine hydroxylase that interacts with nuclear proteins including CROP and U2AF65 which are involved in mRNA splicing. Peptide screening and cell based assays led to the conclusion that JMJD6 catalyses lysine hydroxylation of splicing regulatory proteins containing arginine serine rich domains (SR proteins) including U2AF65 and Luc7like-2. Studies were carried out to investigate the putative arginine demethylation activity of JMJD6 using MS analysis of histone peptides and luminescence-based assays. New substrates from SR proteins were identified by immunoprecipitation of JMJD6 expressed in human cell lines followed by LC-MS/MS analysis and MALDI-MS based assays of synthesised peptide substrates. Work then focussed on studying the mechanism of lysyl-hydroxylation from substrate and enzyme perspective. A crystal structure of seleno-methionine labelled JMJD6 was obtained and it provided insights into the JMJD6 active site and its substrate interactions. Based on this data, single point variants of JMJD6 were prepared and their substrate binding properties were studied by MALDI-MS and 2OG turnover assays. Collagen lysyl-hydroxylases are also 2OG dependent oxygenases. Efforts to investigate the stereochemistry of JMJD6 catalysed hydroxylation, employing NMR and amino acid analyses were carried out. These studies led to the interesting finding that the C-5 stereochemistry of hydroxylysine in LUC7L2 peptide is opposite (2S,5S-hydroxylysine) to that present in collagen (2S,5R-hydroxylysine). It was found that JMJD6 undergoes autocatalytic self-hydroxylation. Lysine residues from both recombinant JMJD6 and that from HeLa cells at endogenous level were identified to be hydroxylated by amino acid and LC-MS/MS analyses. JMJD6 has a strong tendency to form aggregates and gel electrophoresis always reveals multimeric bands of various JMJD6 constructs. Characterisation and identification of oligomeric states of JMJD6 was carried out using Electron Microscopy. Studies were initiated to identify possible inhibitors by screening a set of 2OG analogues. The results from this preliminary inhibition studies have identified the tricarboxylic acid (TCA) cycle intermediates, succinate and fumarate to be JMJD6 inhibitors and form a basis of further studies aimed at identifying selective inhibitors.